[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MAIA Biotechnology’s Chief Scientific Officer Sergei Gryaznov received a grant of 400,000 stock options to acquire common shares at an exercise price of $1.28 per share. These options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan as part of equity-based compensation.

The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining options vesting in equal monthly installments over the following 36 months. After this grant, Gryaznov holds 400,000 stock options directly, according to the filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gryaznov Sergei

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	400,000	$0.00	--

Holdings After Transaction: Stock Options — 400,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options Granted: 400,000 options Exercise Price: $1.28 per share Post-transaction holdings: 400,000 options +3 more

6 metrics

Options Granted 400,000 options Stock options granted to CSO on April 10, 2026

Exercise Price $1.28 per share Conversion or exercise price for the 400,000 options

Post-transaction holdings 400,000 options Total stock options held by CSO after the grant

Vesting Cliff 25% after 1 year Initial vesting on first anniversary of April 10, 2026 grant

Remaining Vesting Period 36 months monthly Balance of options vest ratably monthly over next 36 months

Option Expiration April 10, 2036 Final expiration date of granted options

Key Terms

Stock Options, 2021 Equity Incentive Plan, vesting schedule, grant, award, or other acquisition, +1 more

5 terms

Stock Options financial

"The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

vesting schedule financial

"representing the right to buy shares of common stock, vest on a 4-year vesting schedule"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock, underlying_security_shares: 400000.0000"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gryaznov Sergei

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.28	04/10/2026		A		400,000		04/10/2027(1)	04/10/2036	Common Stock	400,000	$0	400,000	D

Explanation of Responses:

1. The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

	/s/ Sergei M. Gryaznov	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)